Sansheng Jian anti-IL-4R alpha monoantial clinical trial was approved by NMPA.

Endexual dermatitis is a chronic, relapse, inflammatory skin disease, patients often show severe itching symptoms.
patients with moderate to severe endexual dermatitis usually have red rashes on most of their skin, causing intense and persistent itching, dry skin, colic, seepage, which seriously affects the quality of life of the patients.
dermatitis affects 18 to 25 million Americans, and the prevalence of endexual dermatitis in China has been increasing over the past 20 years.
more than 2.3 million adolescents in China are affected by endexual dermatitis, and the number of child patients has reached 2 million to 3 million.
years, with the rapid development of urbanization and industrialization in China, the incidence of special dermatitis in China has gradually increased.
currently, the most widely used corticosteroid drug for the treatment of adiotic dermatitis.
but the more serious side effects of such drugs limit their use, there is still a wide range of unsealed clinical needs for such diseases.
IL-4R alpha is part of the signal conduction complex of interletin 4 (IL-4) and white methicillin 13 (IL-13) and play a key role in the pathogenesis of atopic dermatitis.
611 can alleviate diseases such as endexual dermatitis by inhibiting IL-4R alpha and blocking signaling of IL-4 and IL-13.
611, as a humanized anti-IL-4R alpha monoclonal antibody designed and screened by Sansheng Guojian, has a brand-new amino acid sequence, which is expected to bring new treatment options to patients with specific dermatitis.
.